Krystal Biotech, Inc. Website

Krystal Biotech, Inc.

NasdaqGS-KRYS

Company Overview

Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing KB105 that is in Phase I/II clinical study for treating patients with deficient autosomal recessive congenital ichthyosis; KB301, which is in Phase I/II clinical stage for treating wrinkles and other presentations of aged or damaged skin; KB407 that is in preclinical stage for cystic fibrosis; and KB104, which is in preclinical stage for netherton syndrome. Its discovery stage product candidates include KB5xx for treating chronic skin diseases, KB3xx to treat aesthetic skin conditions, and KB3xx product. Krystal Biotech, Inc. was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania.

  • Name

    Krystal Biotech, Inc.

  • CEO

    Krish S. Krishnan

  • Website

    www.krystalbio.com

  • Sector

    Biotechnology

  • Year Founded

    2016

Company Statistics

Profile

  • Market Cap

    —

  • EV

    —

  • Shares Out

    —

  • Revenue

    —

  • Employees

    —

Margins

  • Gross

    —

  • EBITDA

    —

  • Operating

    —

  • Pre-Tax

    —

  • Net

    —

  • FCF

    —

Returns (5Yr Avg)

  • ROA

    —

  • ROTA

    —

  • ROE

    —

  • ROCE

    —

  • ROIC

    —

Valuation (TTM)

  • P/E

    —

  • P/B

    —

  • EV/Sales

    —

  • EV/EBITDA

    —

  • P/FCF

    —

  • EV/Gross Profit

    —

Valuation (NTM)

  • Price Target

    —

  • P/E

    —

  • PEG

    —

  • EV/Sales

    —

  • EV/EBITDA

    —

  • P/FCF

    —

Financial Health

  • Cash

    —

  • Net Debt

    —

  • Debt/Equity

    —

  • EBIT/Interest

    —

Growth (CAGR)

  • Rev 3Yr

    —

  • Rev 5Yr

    —

  • Rev 10Yr

    —

  • Dil EPS 3Yr

    —

  • Dil EPS 5Yr

    —

  • Dil EPS 10Yr

    —

  • Rev Fwd 2Yr

    —

  • EBITDA Fwd 2Yr

    —

  • EPS Fwd 2Yr

    —

  • EPS LT Growth Est

    —

Dividends

  • Yield

    —

  • Payout

    —

  • DPS

    —

  • DPS Growth 3Yr

    —

  • DPS Growth 5Yr

    —

  • DPS Growth 10Yr

    —

  • DPS Growth Fwd 2Yr

    —

What's happening

Nov 13, 2025 - Dec 13, 2025

Krystal Biotech Inc Surges 20.5% Amid FDA News and Strategic Visibility

  • The FDA granted Priority Review designation for one of Krystal Biotech's products, boosting investor confidence.
  • CEO Krish S. Krishnan showcased the company’s innovative pipeline at a major healthcare conference, enhancing market perception.
  • Despite some insider selling concerns, positive developments outweighed bearish signals during the month.

Over the past month, Krystal Biotech Inc (KRYS) demonstrated strong performance with an overall increase of 20.5%. This marked a significant outperformance compared to the S&P 500, which experienced a slight decline of 0.2% during this period. The stock's upward trajectory was driven by several key developments that captured investor interest and confidence.

A pivotal catalyst for KRYS's rise was the announcement that the FDA granted Priority Review designation for one of its products. Following this news, KRYS saw a notable surge in stock price, increasing by 5.3%. Investors recognized this as an opportunity for expedited New Drug Applications and improved approval chances for their product pipeline. Additionally, Erin Gibbs highlighted KRYS as one of her top picks among small- and mid-cap stocks for 2026, further bolstering bullish sentiment around the company.

The company's visibility at significant industry events also played a crucial role in shaping market perception positively. On December 3rd, CEO Krish S. Krishnan presented at the Evercore Healthcare Conference in Miami where he discussed their innovative pipeline and commercial-stage operations surrounding VYJUVEK®, their first approved redosable gene therapy product. This engagement likely reinforced investor optimism regarding future growth prospects.

Despite these favorable trends, there were brief bearish signals impacting market sentiment; specifically, Chairman Krishnan sold $11 million worth of shares shortly before other positive announcements were made public. While such insider selling can raise concerns about executive confidence in future performance levels among investors, it did not overshadow the overall favorable developments driving KRYS’s stock higher throughout this observation period leading up to early December 2025.

Overall, KRYS significantly outperformed both its sector—Health Care (XLV), which saw lesser gains—and broader market indices like the S&P 500 while benefiting from strategic regulatory designations and strong leadership visibility within healthcare conferences.Krystal Biotech Inc outperformed the Health Care (XLV) sector by 19.7%.

NasdaqGS:KRYS